Biological Effects of C‐peptide and Proinsulin
暂无分享,去创建一个
[1] T. Brismar,et al. Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes. , 2003, Diabetes.
[2] D. Chabardès,et al. C-Peptide stimulates Na+,K+-ATPase activity via PKC alpha in rat medullary thick ascending limb , 2003, Diabetologia.
[3] J. Wahren,et al. C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes. , 2002, Diabetes.
[4] N. Sakane,et al. Proinsulin C-peptide activates cAMP response element-binding proteins through the p38 mitogen-activated protein kinase pathway in mouse lung capillary endothelial cells. , 2002, The Biochemical journal.
[5] J. Johansson,et al. Molecular effects of proinsulin C-peptide. , 2002, Biochemical and biophysical research communications.
[6] J. Johansson,et al. Proinsulin C-peptide and its analogues induce intracellular Ca2+ increases in human renal tubular cells , 2002, Cellular and Molecular Life Sciences CMLS.
[7] L. Heinemann,et al. Effect of C-peptide on glucose metabolism in patients with type 1 diabetes. , 2002, Diabetes care.
[8] C. Berne,et al. Proinsulin Is an Independent Predictor of Coronary Heart Disease: Report From a 27-Year Follow-Up Study , 2002, Circulation.
[9] A. Hsueh,et al. Activation of Orphan Receptors by the Hormone Relaxin , 2002, Science.
[10] S. Jacobson,et al. Effects of C-peptide on glomerular and renal size and renal function in diabetic rats. , 2001, Kidney international.
[11] G. Grunberger,et al. Molecular basis for the insulinomimetic effects of C-peptide , 2001, Diabetologia.
[12] C. Bode,et al. Stimulation in vivo of expression of intra-abdominal adipose tissue plasminogen activator inhibitor Type I by proinsulin , 2001, Diabetologia.
[13] M. Eriksson,et al. Effects of C-peptide on forearm blood flow and brachial artery dilatation in patients with type 1 diabetes mellitus. , 2001, Acta physiologica Scandinavica.
[14] G. Grunberger,et al. C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat , 2001, Diabetologia.
[15] J. Johansson,et al. C-peptide binding to human cell membranes: importance of Glu27. , 2001, Biochemical and biophysical research communications.
[16] N. Sakane,et al. Proinsulin C-peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3T3 fibroblasts: requirement of protein kinase C, phosphoinositide 3-kinase and pertussis toxin-sensitive G-protein. , 2001, The Biochemical journal.
[17] G. Grunberger,et al. C-peptide attenuates protein tyrosine phosphatase activity and enhances glycogen synthesis in L6 myoblasts. , 2001, Biochemical and biophysical research communications.
[18] J. Johansson,et al. Specific binding of proinsulin C-peptide to intact and to detergent-solubilized human skin fibroblasts. , 2001, Biochemical and biophysical research communications.
[19] A. M. Lefer,et al. C‐peptide inhibits leukocyte‐endothelium interaction in the microcirculation during acute endothelial dysfunction , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[20] A. M. Lefer,et al. C-peptide exerts cardioprotective effects in myocardial ischemia-reperfusion. , 2000, American journal of physiology. Heart and circulatory physiology.
[21] A. Saller,et al. Structural involvement in type 1 and type 2 diabetic nephropathy. , 2000, Diabetes & metabolism.
[22] D. Raccah,et al. The effects ex vivo and in vitro of insulin and C-peptide on Na/K adenosine triphosphatase activity in red blood cell membranes of type 1 diabetic patients. , 2000, Metabolism: clinical and experimental.
[23] J. Johansson,et al. Role of C-peptide in human physiology. , 2000, American journal of physiology. Endocrinology and metabolism.
[24] J. Wahren,et al. Beneficial effects of C‐peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus , 2000, Diabetic medicine : a journal of the British Diabetic Association.
[25] J. Wahren,et al. Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+,K+-ATPase activity in diabetes mellitus type I. , 2000, Clinical science.
[26] J. Johansson,et al. Unordered structure of proinsulin C-peptide in aqueous solution and in the presence of lipid vesicles , 2000, Cellular and Molecular Life Sciences CMLS.
[27] L. Luzi,et al. Higher post‐absorptive C‐peptide levels in Type 1 diabetic patients without renal complications , 1999, Diabetic medicine : a journal of the British Diabetic Association.
[28] G Kratz,et al. Specific binding of proinsulin C-peptide to human cell membranes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[29] G. Hallmans,et al. High proinsulin concentration precedes acute myocardial infarction in a nondiabetic population. , 1999, Metabolism: clinical and experimental.
[30] P. K. Thomas,et al. Diabetic neuropathy : mechanisms and future treatment options , 1999 .
[31] Y. Oshida,et al. Rat C peptide I and II stimulate glucose utilization in STZ-induced diabetic rats , 1999, Diabetologia.
[32] K. Sugimoto,et al. Experimental diabetic neuropathy: an update , 1999, Diabetologia.
[33] E. Messina,et al. C-peptide induces a concentration-dependent dilation of skeletal muscle arterioles only in presence of insulin. , 1999, American journal of physiology. Heart and circulatory physiology.
[34] T. Forst,et al. The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus , 1999, Diabetologia.
[35] P. Jehle,et al. High affinity binding sites for proinsulin on human umbilical vein endothelial cells (HUVEC) , 1999, Diabetologia.
[36] A. Hiura,et al. Insulinoma with hyperproinsulinemia during hypoglycemia and loss of expression of vacuolar-type H+-ATPase (V-ATPase) in the tumor tissue , 1999, International journal of pancreatology : official journal of the International Association of Pancreatology.
[37] O. Madsen,et al. Functioning human insulinomas , 1998, Virchows Archiv.
[38] P K Thomas,et al. Diabetes mellitus and the nervous system , 1998, Journal of neurology, neurosurgery, and psychiatry.
[39] M. Sjöquist,et al. Effects of C-peptide on renal function at the early stage of experimental diabetes. , 1998, Kidney international.
[40] D. Raccah,et al. Erythrocyte Na/K ATPase activity and diabetes: relationship with C-peptide level , 1998, Diabetologia.
[41] M. Cooper,et al. Pathogenesis, prevention, and treatment of diabetic nephropathy , 1998, The Lancet.
[42] L. Luzi. Pancreas transplantation and diabetic complications. , 1998, The New England journal of medicine.
[43] D. Sutherland,et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. , 1998, The New England journal of medicine.
[44] T. Forst,et al. Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus. , 1998, The Journal of clinical investigation.
[45] H. Jörnvall,et al. Differential effects of proinsulin C-peptide fragments on Na +, K +-ATPase activity of renal tubule segments , 1998, Diabetologia.
[46] P. Halban,et al. Release of Incompletely Processed Proinsulin Is the Cause of the Disproportionate Proinsulinemia of NIDDM , 1997, Diabetes.
[47] X. Navarro,et al. Long‐term effects of pancreatic transplantation on diabetic neuropathy , 1997, Annals of neurology.
[48] W. Webb,et al. Fluorescence correlation spectroscopy: diagnostics for sparse molecules. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[49] P. Oskarsson,et al. Effects of C‐peptide on insulin‐induced hypoglycaemia and its counterregulatory responses in IDDM patients , 1997, Diabetic medicine : a journal of the British Diabetic Association.
[50] E. Di Cera,et al. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. , 1997, Science.
[51] D. Steiner,et al. Proinsulin C-Peptide-Biological Activity? , 1997, Science.
[52] M. Foppiano,et al. Worldwide pharmacovigilance systems and tolrestat withdrawal , 1997, The Lancet.
[53] T. Hohman,et al. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats , 1997, Diabetologia.
[54] J. Wahren,et al. C-peptide improves autonomic nerve function in IDDM patients , 1996, Diabetologia.
[55] Y. Oshida,et al. Effect of C-peptide administration on whole body glucose utilization in STZ-induced diabetic rats. , 1996, Acta physiologica Scandinavica.
[56] H. Vlassara,et al. Protein glycation in the kidney: role in diabetes and aging. , 1996, Kidney international.
[57] P. Jehle,et al. High affinity binding sites for proinsulin in human IM-9 lymphoblasts , 1996, Diabetologia.
[58] J. Zierath,et al. C-peptide stimulates glucose transport in isolated human skeletal muscle independent of insulin receptor and tyrosine kinase activation , 1996, Diabetologia.
[59] J. Wahren,et al. C-peptide stimulates rat renal tubular Na+, K+-ATPase activity in synergism with neuropeptide Y , 1996, Diabetologia.
[60] G. Jerums,et al. Extracellular matrix and its interactions in the diabetic kidney: a molecular biological approach. , 1995, Journal of diabetes and its complications.
[61] E. Feldman,et al. The linked roles of nitric oxide, aldose reductase and, (Na+,K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. , 1994, The Journal of clinical investigation.
[62] M. Eigen,et al. Sorting single molecules: application to diagnostics and evolutionary biotechnology. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[63] J. Bourguignon,et al. Gonadotropin releasing hormone inhibitory autofeedback by subproducts antagonist at N-methyl-D-aspartate receptors: a model of autocrine regulation of peptide secretion. , 1994, Endocrinology.
[64] J. Wahren,et al. Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of Type 1 (insulin-dependent) diabetic patients , 1992, Diabetologia.
[65] M. Steffes,et al. An overview of renal pathology in insulin-dependent diabetes mellitus in relationship to altered glomerular hemodynamics. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[66] B. Sobel,et al. Stimulation by Proinsulin of Expression of Plasminogen Activator Inhibitor Type-I in Endothelial Cells , 1992, Diabetes.
[67] D. Howey,et al. Biosynthetic Human Proinsulin: Review of Chemistry, in Vitro and in Vivo Receptor Binding, Animal and Human Pharmacology Studies, and Clinical Trial Experience , 1992, Diabetes Care.
[68] Jeppe Sturis,et al. Estimation of Insulin Secretion Rates from C-Peptide Levels: Comparison of Individual and Standard Kinetic Parameters for C-Peptide Clearance , 1992, Diabetes.
[69] J. Wahren,et al. The influence of human C-peptide on renal function and glucose utilization in Type 1 (insulin-dependent) diabetic patients , 1992, Diabetologia.
[70] J. Zierath,et al. Effect of human C-peptide on glucose transport in in vitro incubated human skeletal muscle , 1991, Diabetologia.
[71] J. Wahren,et al. Renal and splanchnic exchange of human biosynthetic C-peptide in Type 1 (insulin-dependent) diabetes mellitus , 1991, Diabetologia.
[72] P. Winocour,et al. A Randomized Cross‐over Study of the Effects of Proinsulin on Lipid Metabolism in Type 2 Diabetes , 1991, Diabetic medicine : a journal of the British Diabetic Association.
[73] I. Shalit,et al. All‐D‐magainin: chirality, antimicrobial activity and proteolytic resistance , 1990, FEBS letters.
[74] C. Mogensen. Prediction of Clinical Diabetic Nephropathy in IDDM Patients: Alternatives to Microalbuminuria? , 1990, Diabetes.
[75] C. Hales,et al. RADIOIMMUNOASSAY MAY OVERESTIMATE INSULIN IN NON‐INSULIN‐DEPENDENT DIABETICS , 1990, Clinical endocrinology.
[76] P. Bennett,et al. Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus. , 1990, The Journal of clinical endocrinology and metabolism.
[77] D. Owens,et al. INSULIN DEFICIENCY IN NON-INSULIN-DEPENDENT DIABETES , 1989, The Lancet.
[78] J. Patsch,et al. Effects of biosynthetic human proinsulin on plasma lipids in type 2 diabetes mellitus , 1988, Klinische Wochenschrift.
[79] P. Gruppuso,et al. Binding of proinsulin and proinsulin conversion intermediates to human placental insulin-like growth factor I receptors. , 1988, The Journal of clinical endocrinology and metabolism.
[80] R. Østerby,et al. Glomerular Morphology by Light Microscopy in Non-Insulin-Dependent Diabetes Mellitus: Lack of Glomerular Hypertrophy , 1988, Diabetes.
[81] J. Bülow,et al. Kinetics of circulating endogenous insulin, C-peptide, and proinsulin in fasting nondiabetic man. , 1987, Metabolism: clinical and experimental.
[82] A. Lefvert,et al. Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term Type 1 (insulin-dependent) diabetes mellitus , 1987, Diabetologia.
[83] E Ernst,et al. Altered Red and White Blood Cell Rheology in Type II Diabetes , 1986, Diabetes.
[84] P. Palatini,et al. Reduction of erythrocyte (Na+-K+)ATPase activity in Type 1 (insulin-dependent) diabetic subjects and its activation by homologous plasma , 1986, Diabetologia.
[85] K. Polonsky,et al. Ingestion of a mixed meal does not affect the metabolic clearance rate of biosynthetic human C-peptide. , 1986, The Journal of clinical endocrinology and metabolism.
[86] B. Brenner,et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. , 1986, The Journal of clinical investigation.
[87] V. Towle,et al. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes. , 1986, Metabolism: clinical and experimental.
[88] J. Olefsky,et al. Kinetics of Biosynthetic Human Proinsulin Action in Isolated Rat Adipocytes , 1986, Diabetes.
[89] S. Hampton,et al. Specific binding of the C-peptide of proinsulin to cultured B-cells from a transplantable rat islet cell tumor , 1986, Bioscience reports.
[90] B. Hoogwerf,et al. Infusion of synthetic human C-peptide does not affect plasma glucose, serum insulin, or plasma glucagon in healthy subjects. , 1986, Metabolism: clinical and experimental.
[91] A. Krolewski,et al. The changing natural history of nephropathy in type I diabetes. , 1985, The American journal of medicine.
[92] W. Duckworth,et al. In Vitro Activity of Biosynthetic Human Proinsulin: Receptor Binding and Biologic Potency of Proinsulin and Insulin in Isolated Rat Adipocytes , 1984, Diabetes.
[93] K. Polonsky,et al. The Effects of Biosynthetic Human Proinsulin on Carbohydrate Metabolism , 1984, Diabetes.
[94] K. Polonsky,et al. C-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations , 1984, Diabetes.
[95] W. Waldhäusl,et al. Hepatic disposal of biosynthetic human insulin and porcine C-peptide in humans. , 1984, Metabolism: clinical and experimental.
[96] J. Olefsky,et al. In Vitro Characterization of Biosynthetic Human Proinsulin , 1984, Diabetes.
[97] C. Ronco,et al. Renal functional reserve in humans. Effect of protein intake on glomerular filtration rate. , 1983, The American journal of medicine.
[98] G. Slama,et al. Progressive centripetal degeneration of axons in small fibre diabetic polyneuropathy. , 1983, Brain : a journal of neurology.
[99] E. Pfeiffer,et al. Effects of synthetic rat C-peptide in normal and diabetic rats , 1983, Diabetologia.
[100] K. Polonsky,et al. Metabolism of C-peptide in the dog. In vivo demonstration of the absence of hepatic extraction. , 1983, The Journal of clinical investigation.
[101] K. M. Erickson,et al. Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. , 1980, The Journal of clinical endocrinology and metabolism.
[102] J. M. May,et al. Characterization of proinsulin-insulin intermediates in human plasma. , 1978, The Journal of clinical investigation.
[103] D. McMillan,et al. Reduced Erythrocyte Deformability in Diabetes , 1978, Diabetes.
[104] D L Horwitz,et al. Kinetics of human connecting peptide in normal and diabetic subjects. , 1978, The Journal of clinical investigation.
[105] A. Moses,et al. Proinsulin binds to a growth peptide receptor and stimulates DNA synthesis in chick embryo fibroblasts. , 1977, Endocrinology.
[106] H. Kuzuya,et al. Abnormalities in circulating beta cell peptides in chronic renal failure: comparison of C-peptide, proinsulin and insulin. , 1977, The Journal of clinical endocrinology and metabolism.
[107] L. Heding. Radioimmunological determination of human C-peptide in serum , 1975, Diabetologia.
[108] P. Freychet. The interactions of proinsulin with insulin receptors on the plasma membrane of the liver. , 1974, The Journal of clinical investigation.
[109] S. Yu,et al. Biological activity of proinsulin and related polypeptides in the fat tissue. , 1973, The Journal of biological chemistry.
[110] A. Katz,et al. Metabolism of proinsulin, insulin, and C-peptide in the rat. , 1973, The Journal of clinical investigation.
[111] H. H. Sørensen,et al. Assay of insulin-like activity by the isolated fat cell method IV. The biological activity of proinsulin , 1970, Diabetologia.
[112] D. Steiner,et al. Secretion of Proinsulin C-Peptide by Pancreatic β Cells and its Circulation in Blood , 1969, Nature.
[113] D. Steiner,et al. The biosynthesis of insulin and a probable precursor of insulin by a human islet cell adenoma. , 1967, Proceedings of the National Academy of Sciences of the United States of America.
[114] V. Vallon,et al. Human C-peptide acutely lowers glomerular hyperfiltration and proteinuria in diabetic rats: a dose-response study , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.
[115] C. Pierson,et al. Human C-peptide Dose Dependently Prevents Early Neuropathy in the BB/Wor-rat , 2001, International journal of experimental diabetes research.
[116] D. Steiner. New Aspects of Proinsulin Physiology and Pathophysiology , 2000, Journal of pediatric endocrinology & metabolism : JPEM.
[117] J. Pernow,et al. C-peptide potentiates the vasoconstrictor effect of neuropeptide Y in insulin-dependent diabetic patients. , 1999, Acta physiologica Scandinavica.
[118] B. Haraldsson,et al. Acute effects of C-peptide on the microvasculature of isolated perfused skeletal muscles and kidneys in rat. , 1996, Acta physiologica Scandinavica.
[119] L. Berglund,et al. Residual C-peptide excretion is associated with a better long-term glycemic control and slower progress of retinopathy in type I (insulin-dependent) diabetes mellitus. , 1991, The Journal of diabetic complications.
[120] K. Polonsky,et al. Current approaches to measurement of insulin secretion. , 1986, Diabetes/metabolism reviews.
[121] Bruce H. Frank,et al. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. , 1986, The Journal of clinical investigation.
[122] L. O. Simpson,et al. Intrinsic stiffening of red blood cells as the fundamental cause of diabetic nephropathy and microangiopathy: a new hypothesis. , 1985, Nephron.